12/27/2013 8:34:02 AM
PLYMOUTH, Mich.--(BUSINESS WIRE)--Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on December 23, 2013. The Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market(R) (NASDAQ(R)) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). This is the most recent index to which the company has been added in 2013. The company is also included in the Russell Global, 3000, 2000, and Microcap indices, and the MSCI Global Micro Cap indices.
Help employers find you! Check out all the jobs and post your resume.
comments powered by